RegenMed


# ARTICLE

## ORTHOPEDIC INNOVATION: VALIDATING HYPOTHESES IN MSK FUNCTIONAL RECOVERY

www.rgnmed.com | circles@rgnmed.com

## EXECUTIVE SUMMARY: FROM STRUCTURAL REPAIR TO FUNCTIONAL RESTORATION

The field of orthopedics is undergoing a fundamental shift in its value proposition. For decades, the specialty's economic engine has been fueled by surgical volume — specifically total joint arthroplasty (TJA) and arthroscopic interventions. However, the 2026 introduction of the **CMS ACCESS model** and the **Veracity Mandate** has introduced a new metric of success: the objective validation of functional recovery. For clinical department heads and medical directors, this necessitates a transition from a "structural repair" mindset to one of "functional restoration." By leveraging high-fidelity real-world evidence (RWE) and "Circle Datasets," orthopedic leaders can now validate clinical hypotheses regarding regenerative therapies and non-operative care, transforming "experimental" treatments into high-value, reimbursable assets.

## THE MSK GAP: THE TENSION BETWEEN VOLUME AND VALUE

Musculoskeletal (MSK) conditions represent a primary driver of healthcare spending in the United States, with chronic pain affecting more than two-thirds of Medicare beneficiaries. Historically, the "orthopedic gap" has been defined by a lack of objective, longitudinal data connecting conservative management to long-term surgical avoidance.

- **The Limitations of Imaging:** Traditional diagnostics (X-ray, MRI) focus on structural anomalies which often correlate poorly with a patient's actual pain or functional level.
- **The "Unproven" Label:** Regenerative treatments such as Platelet-Rich Plasma (PRP) and Bone Marrow Aspirate Concentrate (BMAC) have long been sidelined as elective or investigational due to a lack of standardized Phase III trial data and variable preparation protocols.
- **The Surgical Default:** In a fee-for-service (FFS) environment, the financial incentive favored surgical intervention over prolonged conservative management, even when outcomes were comparable for certain conditions like meniscal tears or rotator cuff disease.

# THE ACCESS MSK TRACK: FUNCTIONAL TARGETS AS THE NEW GOLD STANDARD

The CMS ACCESS model, launched in July 2026, explicitly addresses this gap by introducing **Outcome-Aligned Payments (OAPs)** for chronic MSK pain.

### The Role of Validated PROMs

Under ACCESS, the "Outcome Attainment Rate" (OAR) is determined by a patient's improvement relative to their own baseline. The model prioritizes validated Patient-Reported Outcome Measures (PROMs) to quantify this improvement:

- **KOOS Jr (Knee Injury and Osteoarthritis Outcome Score):** A 7-item survey measuring stiffness, pain, and function specifically for knee health.
- **HOOS Jr (Hip dysfunction and Osteoarthritis Outcome Score):** The hip-specific counterpart used to guide decision-making and track recovery.
- **Minimal Clinically Important Difference (MCID):** Success is defined not by perfection, but by hitting the MCID — the smallest change in a score that a patient perceives as beneficial.

By tying 50% of the OAP revenue to these functional metrics, CMS has effectively turned PROMs from a quality metric into a financial control.

# HYPOTHESIS VALIDATION VIA CIRCLE DATASETS

To thrive in the ACCESS environment, orthopedic clinicians must move beyond subjective reporting. Circle Datasets provide the high-veracity infrastructure required to prove the efficacy of innovative pathways.

### Validating Regenerative Efficacy

Orthopedic innovators can use these datasets to validate hypotheses regarding regenerative biologics:

- **Standardizing Biologics:** Circle Datasets allow practices to track the specific "dose" and "preparation" of PRP or BMAC alongside the resulting functional score. This eliminates the variability that previously prevented universal insurance coverage.

- **RWE for Regulatory Submission:** By capturing these outcomes in real-life settings, providers can generate the Real-World Evidence (RWE) required by the FDA TEMPO pilot to move "investigational" biologics toward full market authorization.

- **Predictive Modeling:** Advanced analytics can identify "super-responders" to regenerative therapy, allowing medical directors to engineer pathways that prioritize these treatments for patients most likely to hit their ACCESS functional targets.

## OBJECTIVE RECOVERY: THE SHIFT TO SENSOR-BASED KINEMATICS

While PROMs are essential, they remain subjective. The 2026 standard for functional recovery increasingly incorporates objective, sensor-based data to confirm "Proven Medical Accuracy".

- **Beyond In-Person PT:** Traditional physical therapy (PT) often suffers from poor adherence and subjective assessment. Telerehabilitation and wearable sensors provide real-time visual and clinical feedback.

- **Neuromuscular Adaptation:** Sensors can track specific metrics like surface EMG (sEMG) for motor unit recruitment or Timed Up and Go (TUG) performance. Studies have shown that sensor-based interventions can result in superior neuromuscular adaptation compared to conventional PT.

- **Fall Risk Mitigation:** Objective balance measures and functional mobility data can exceed the MCID, providing verifiable proof of reduced fall risk in older populations — a key metric for Medicare-aligned panels.

## ECONOMIC REALIGNMENT: PREVENTING "SUBSTITUTE SPEND"

The most significant financial opportunity for orthopedic leaders in 2026 lies in managing **Substitute Spend**—the volume of high-cost services (like premature surgery or ER visits) patients seek outside the managed pathway.

- **The Surgery-Avoidance Premium:** If an orthopedic practice can use sensor-based PT and regenerative biologics to keep a patient functional and pain-free, they justify the OAP and avoid the "leakage penalty" associated with patients undergoing surgery elsewhere.

- **The Liability Shield:** Verified functional outcomes serve as an immutable record of clinical success. In the event of a dispute, the "Outcome Shield" proves that the non-operative pathway was medically appropriate and successful, reducing the risk of malpractice claims linked to "failure to operate".

- **Tech-Enabled Asset Valuation:** By demonstrating that the practice can consistently hit functional targets through an engineered pathway, the organization moves from a low-multiple "service business" to a high-multiple "tech-enabled asset".

## STRATEGIC IMPLICATIONS FOR MEDICAL DIRECTORS

- **Mandate Baseline Precision:** Success in ACCESS is relative to the baseline. Ensure that every patient has a high-fidelity functional baseline (KOOS/HOOS Jr) before any intervention begins.

- **Adopt "Outcome Engineering":** Design pathways that sequence regenerative biologics and sensor-based PT based on their probability of hitting the MCID within the 12-month care period.

- **Monetize the Intellect:** Use Circle Datasets to capture the "ground truth" of your innovative protocols. This data is an asset that can be licensed to life-sciences partners or used to negotiate volume-based discounts with insurers.

- **Incentivize Functional Success:** Realign internal compensation for surgeons and clinicians around "Outcome Attainment Rates" rather than RVU-based procedural volume.

## CONCLUSION

Orthopedic innovation in 2026 is no longer just about a sharper scalpel or a better implant; it is about the verifiable restoration of human function. The ACCESS and TEMPO models provide the financial and regulatory framework to finally move MSK care into a value-based reality. By embracing Circle Datasets and objective functional metrics, orthopedic leaders can validate their clinical hypotheses, protect their professional sovereignty, and drive significant business growth in an environment that prizes "Proven Medical Accuracy" above all else.

## SOURCES


1. Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS, JR) - APTA
2. Osteoarthritis & Joint Replacement Outcome Surveys - HSS
3. Hip & Knee Osteoarthritis Standard Set | Measuring Outcomes - ICHOM
4. MSK5 - Patients Suffering From a Knee Injury who Improve Physical Function | Healthmonix
5. Does Insurance Cover PRP or BMAC? | Regenerative Medicine Coverage Guide
6. Regenerative Injection Therapy Cost: 2025 Unveiled - California Pain Consultants
7. 2025 PRP fact-check and review: cost and possible benefits - The Niche
8. ACCESS Technical Frequently Asked Questions - CMS
9. ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model | CMS
10. ACCESS Model: CMMI's New Technology-Enabled Chronic Care Model - Health Law Advisor
11. Wearable Sensor–Based Telerehabilitation Versus Conventional Physiotherapy in Knee OA - MDPI
12. Academy of Orthopaedic Physical Therapy Platform Presentation Abstracts OPL1-OPL68 | JOSPT Open
13. Comparing Digital to Conventional Physical Therapy for Chronic Shoulder Pain: Randomized Controlled Trial - PMC
14. CMMI Launches Application Process for ACCESS Model: A New, Outcome-Focused Value-Based Payment Model - Dentons
15. In ACCESS, CMMI Tests an Outcome-Aligned Path for Chronic Care - Applied Policy
16. The Dawn of Outcome-Aligned Care: Understanding the Transformative ACCESS Model - Becker's Hospital Review

# GET INVOLVED OR LEARN MORE — CONTACT US TODAY!

If you are interested in contributing to this important initiative or learning more about how you can be involved, please contact us*:

RegenMed | www.rgnmed.com

circles@rgnmed.com

SCAN ME

*If the links do not work for you, please download the PDF.